Lantus International Purchase Legalities: What U.S. Patients Need to Know in 2026

The Core Legal Problem With Buying Lantus Abroad

The Federal Food, Drug, and Cosmetic Act (FD&C Act), codified at 21 U.S.C. § 331, prohibits the importation of any unapproved drug into the United States. Lantus purchased from a Canadian or other foreign pharmacy is not FDA-approved, it is approved by Health Canada or another national regulator, a legally distinct approval that does not transfer. The FDA has stated this clearly: "It is generally illegal for individuals to import drugs into the United States." [1]

The law and the agency's actual enforcement behavior are not the same thing.

What the FDA's Personal Importation Policy Actually Says

The FDA's personal importation policy, documented in its Compliance Policy Guide Sec. 110.310, provides enforcement discretion, not a legal exemption. Under this guidance, FDA officers may choose not to detain a personal shipment when all of the following conditions are met:

• The product is for personal use, not resale.
• The quantity does not exceed a 90-day supply.
• No significant public health risk is present.
• The product is not for a serious condition for which effective U.S. Treatment is unavailable, or the patient affirms the foreign product is for a condition not adequately treated by available U.S. Drugs. [1]

The word "may" is not accidental. Customs and Border Protection can still seize the package. The FDA can still refer the matter for prosecution. In practice, individual insulin shipments are rarely seized, but zero legal protection exists for the purchaser.

State-Level Importation Programs: A Different Category

Florida, Colorado, and roughly a dozen other states have passed laws authorizing state-run drug importation programs under Section 804 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Florida's program received FDA authorization in January 2024, the first state program to do so. [2] These programs operate through licensed wholesalers, supply verified Canadian drug supplies to state-distributed channels, and are legally distinct from an individual buying insulin on a foreign website. Patients in participating states may eventually access lower-cost insulin glargine through these channels, though product availability in state programs changes frequently and should be confirmed with state health departments.

How Much Cheaper Is Lantus Outside the United States?

The price gap is not a rumor. The 2021 RAND Corporation report found that U.S. Drug prices are 2.56 times higher on average than prices in 32 other OECD nations, with insulin showing some of the largest absolute disparities. [3] Lantus (insulin glargine 100 units/mL, 10 mL vial) carries a U.S. Wholesale acquisition cost of approximately $292 per vial as of 2025. The same product in Canada retails for the equivalent of roughly $35, $50 USD.

Verified Price Data Points

A 2019 study in JAMA Internal Medicine (Lipska et al., N=analyzed national pharmacy data) documented that U.S. Insulin list prices tripled between 2002 and 2013, with list prices continuing to rise through 2019 before manufacturer cap programs began moderating out-of-pocket exposure. [4] The actual price paid by insured patients differs significantly from WAC, but uninsured patients historically faced the full list price.

Sanofi responded to this pressure in stages:

1. The Insulins Valyou Savings Program caps out-of-pocket costs at $99/month for all Sanofi insulins, including Lantus, for eligible uninsured or underinsured patients.
2. In January 2023, Sanofi announced a 78% reduction in Lantus list price, bringing it to approximately $130 per vial, though net prices after rebates had already been lower for insured patients.
3. The Inflation Reduction Act of 2022 capped insulin cost-sharing at $35/month for Medicare Part D enrollees beginning January 1, 2023. [5]

The Uninsured Patient's Actual Options

For patients without insurance, the arithmetic still favors domestic legal pathways over international importation risk:

• Basaglar (insulin glargine biosimilar, Eli Lilly) lists at approximately 15 to 20% below Lantus and is available through the Lilly Insulin Value Program at $35/month.
• Semglee (insulin glargine-yfgn, Viatris/Biocon), the first interchangeable basal insulin biosimilar, launched at 65% below Lantus list price in September 2021. [6]
• Rezvoglar (insulin glargine-aglr, Eli Lilly) received FDA approval as an interchangeable biosimilar in December 2022 and launched at $92 per vial list price.

How the FDA Defines "Personal Use" for Importation

The 90-day supply threshold is the most commonly cited number, but it is only one factor. The FDA's guidance document on personal importation states that agency personnel should consider whether "the product is clearly for personal use (e.g., a relatively small quantity is being imported and there is no evidence of commercial sale)." [1]

Quantity, Labeling, and Country of Origin

A single 90-day insulin supply for a typical Type 1 patient on basal-bolus therapy might be 2 to 3 vials of glargine. Shipments significantly exceeding that volume, or shipments bearing labeling in a foreign language without English translation of dosing and safety information, increase seizure risk materially. The FDA also scrutinizes shipments from countries without equivalent regulatory standards; Canada and the United Kingdom carry lower risk profiles than unregulated online pharmacies based in countries without strong drug oversight.

Verified Canadian Internet Pharmacies: CIPA and VIPPS

The Canadian International Pharmacy Association (CIPA) maintains a list of certified member pharmacies. The National Association of Boards of Pharmacy (NABP) operates the Verified Internet Pharmacy Practice Sites (VIPPS) accreditation, which includes some Canadian-affiliated dispensaries. Purchasing from a CIPA-certified or NABP-accredited pharmacy reduces (but does not eliminate) the risk of receiving counterfeit or subpotent product. Patients should verify that any foreign pharmacy requires a valid prescription, pharmacies that sell insulin without one are operating outside Canadian law as well.

Domestic Legal Alternatives to International Purchase

The following decision framework, developed by the HealthRX clinical team, organizes domestic cost-reduction pathways by insurance status. It is reviewed for accuracy against current program terms as of Q1 2026.

Pathway 1: Insured Patients With High Cost-Sharing

1. Request an interchangeable biosimilar substitution. Pharmacists in all 50 states may substitute an interchangeable biosimilar (Semglee, Rezvoglar) without a new prescription under state pharmacy practice acts aligned with FDA's interchangeability designation. [6]
2. Apply a manufacturer copay card. Sanofi's copay program reduces Lantus cost-sharing to as low as $0 for commercially insured patients who qualify.
3. Confirm Medicare Part D enrollment and the $35 cap. The $35/month insulin cap under the Inflation Reduction Act applies to all Medicare Part D plans as of January 1, 2023, and does not require a low-income subsidy. [5]

Pathway 2: Uninsured Patients

1. Apply directly to Sanofi's Insulins Valyou Savings Program (healthrx.com links to the enrollment page). Income verification is required; the cap is $99/month for all covered products.
2. Contact the Sanofi Patient Assistance Program (Sanofi Connection) for free product if income is below 400% of the federal poverty level.
3. Evaluate switching to Semglee or Rezvoglar. Both are FDA-designated as interchangeable with Lantus. A prescriber note confirming therapeutic equivalence takes under five minutes to generate.
4. Check GoodRx, NeedyMeds, or RxAssist for local pharmacy pricing. GoodRx-negotiated prices for a 10 mL vial of Semglee have appeared below $75 at major pharmacy chains.

Pathway 3: Patients Considering Over-the-Counter Insulin as a Bridge

Regular insulin (Novolin R, Humulin R) and NPH insulin (Novolin N, Humulin N) remain available over the counter at Walmart for $25 per vial under the ReliOn brand. These are not glargine analogs and carry different pharmacokinetic profiles, most notably, they lack the 24-hour flat action curve of insulin glargine and require more frequent dosing. The American Diabetes Association Standards of Care 2024 notes that "use of human insulin instead of analog insulin may be necessary due to cost but is associated with higher hypoglycemia risk in some patients." [7] Transition back to glargine should occur as soon as cost barriers are resolved.

What Happens When Insulin Is Seized at the Border?

CBP and FDA can detain, refuse entry to, or destroy imported drug products. The importer of record (the patient, in personal importation) receives a written notice of refusal. No fine or criminal charge typically follows a single personal-use seizure, but the shipment is lost and the insulin supply gap becomes a clinical emergency for insulin-dependent patients.

Patients planning to travel internationally with personal insulin supplies face a separate issue: the Transportation Security Administration allows insulin and related supplies in carry-on luggage without the 3.4-ounce liquid limit, provided they are clearly labeled. [8] This is travel with a personal supply, not importation for ongoing domestic use, and carries no legal risk.

Clinical Considerations: Is Foreign-Sourced Glargine the Same Product?

Pharmacologically, insulin glargine manufactured by Sanofi for the Canadian market uses the same active pharmaceutical ingredient and the same recombinant DNA production process as U.S.-marketed Lantus. The difference is regulatory jurisdiction, not molecular structure. However, cold-chain integrity during international shipping is a real concern. Insulin glargine must be stored at 2 to 8°C (refrigerated) before opening and should not be frozen or exposed to temperatures above 30°C. [9] Packages shipped via unregulated online pharmacies may have no verifiable temperature control during transit.

A 2023 analysis in Diabetes Care examining insulin potency from unregulated online sources found that 14 of 35 sampled vials (40%) had measurable deviations from labeled potency, with 6 samples falling below 80% of labeled activity. [10] Subpotent insulin in a Type 1 patient is a direct path to diabetic ketoacidosis.

Biosimilar Glargine: Same Molecule, U.S.-Approved, Cheaper

The FDA's interchangeability designation for Semglee (granted September 2021) means a pharmacist can substitute it for Lantus without physician intervention, and clinical outcomes should be identical. [6] The INSTRIDE 1, 2, and 3 trials (combined N>700 patients with Type 1 and Type 2 diabetes) demonstrated that MYL-1501D (Semglee) was pharmacokinetically and pharmacodynamically equivalent to Lantus, with no difference in HbA1c reduction or hypoglycemia rates at 24 weeks. [11]

Regulatory Updates Through 2025 and Into 2026

Several regulatory changes affect the practical calculus for patients in 2025 and 2026:

• The Inflation Reduction Act's insulin provisions remain intact as of the time of publication. The $35 Medicare cap is statutory. [5]
• Florida's Section 804 importation program began distributing Canadian-sourced drugs through state agencies in 2024. Expansion to additional products, potentially including insulin, is under review by the Florida Agency for Health Care Administration.
• The FDA's Drug Importation Action Plan, published in 2020, outlined a framework for future personal importation rule-making that has not yet resulted in a final rule. The enforcement discretion policy therefore remains the operative guidance. [1]
• Sanofi's list-price reduction to approximately $130/vial for Lantus became effective May 1, 2023, bringing U.S. Pricing closer to (though still above) Canadian retail levels.

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes states: "Insulin access and affordability are critical safety issues. Clinicians should proactively assess the ability of patients to afford and access insulin and make cost-reducing switches when indicated." [7]

HSA and FSA Coverage for Lantus

Insulin became HSA/FSA-eligible without a prescription effective January 1, 2020, under the CARES Act (P.L. 116-136). [12] This applies to all insulin formulations, including Lantus and its biosimilars. A patient paying out of pocket through a high-deductible health plan can use pre-tax dollars to purchase Lantus, effectively reducing the after-tax cost by their marginal tax rate. For a patient in the 22% federal bracket, a $130 vial costs approximately $101.40 in pre-tax dollars when purchased through an HSA.

FSA funds are subject to the use-it-or-lose-it rule (with a limited rollover provision of $640 for 2024 plan years). Patients with large remaining FSA balances near year-end should consider using those funds to purchase a 90-day supply of Lantus or an interchangeable biosimilar before the forfeiture date.